Nephros Announces Financial Results for Quarter Ended September 30, 2024
Rhea-AI Summary
Nephros reported Q3 2024 financial results with net revenue of $3.5 million, marking an 8% increase over Q2 2024 but a 6% decrease from Q3 2023. The company achieved its first profitable quarter with net income of $0.2 million, compared to a net loss of $0.2 million in Q3 2023. Gross margins improved to 61% from 59% year-over-year. Adjusted EBITDA reached $295,000, up from $11,000 in the same period last year. Cash position stood at $2.5 million as of September 30, 2024, down from $4.3 million at the end of 2023.
Positive
- First profitable quarter achieved with $0.2M net income vs $0.2M loss in Q3 2023
- Gross margins improved to 61% from 59% year-over-year
- Adjusted EBITDA increased to $295,000 from $11,000 in Q3 2023
- 8% revenue growth quarter-over-quarter
- Operating expenses decreased due to reduced bonus accrual and stock compensation
Negative
- Revenue declined 6% year-over-year to $3.5M from $3.7M
- South Central region continues to underperform expectations
- Cash position decreased to $2.5M from $4.3M at year-end 2023
- Slower-than-usual ordering patterns from larger accounts
- Decrease in same-site sales
News Market Reaction 1 Alert
On the day this news was published, NEPH gained 3.87%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Third-Quarter Net Revenue of
Operational Improvements Result In First Profitable Quarter
SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024.
Financial Highlights*
- Net income of
$0.2 million , compared to a net loss of$0.2 million - Adjusted EBITDA of
$295,000 , compared to$11,000 - Net revenue of
$3.5 million , an8% increase over Q2 2024; a decrease of6% over Q3 prior year
*Stated performance is relative to same period in the prior year unless otherwise noted.
“I am very excited to report our first profitable quarter, marking a major milestone in our pursuit of achieving operational excellence. I am also pleased to report we had positive-adjusted EBITDA for both the third quarter and first nine months of 2024,” stated Robert Banks, President and Chief Executive Officer. “Although most of our sales regions showed solid growth and steady performance with existing customers, our [South Central] region continued to miss expectations, which resulted in some reorganization. Additionally, a handful of our larger accounts exhibited slower-than-usual ordering patterns, as demonstrated by a slight decrease in same-site sales. We continue to push forward with actions designed to mitigate the reduction in programmatic reorders, as outlined during our previous earnings call.”
Mr. Banks continued, “While Nephros prepares to launch digital support for filter installation, we are ramping up our service capabilities to foster installation commissions and complement filter sales. We believe these efforts will offset customer non-compliance with filter changeout schedules.”
Financial Performance for the Quarter Ended September 30, 2024
Net revenue for the quarter ended September 30, 2024, was
Cost of goods sold for the quarter ended September 30, 2024, was
Research and development expenses for each of the quarters ended September 30, 2024, and September 30, 2023, were
Selling, general and administrative expenses for the quarter ended September 30, 2024, was
Net income for the quarter ended September 30, 2024, was
Adjusted EBITDA for the quarter ended September 30, 2024, was
As of September 30, 2024, Nephros had cash and cash equivalents of
Adjusted EBITDA Definition and Reconciliation to GAAP Financial Measures
Adjusted EBITDA is calculated by taking net loss calculated in accordance with generally accepted accounting principles (“GAAP”) and excluding all interest-related expenses and income, tax-related expenses and income, non-recurring expenses and income, and non-cash items, including depreciation, amortization, non-cash inventory write-offs, and non-cash compensation. The following tables present a reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure, for the third quarter and year to date of the 2024 and 2023 fiscal years:
| (unaudited) | ||||
| Three Months Ended September 30, | ||||
| Consolidated Results | 2024 | 2023 | ||
| (in $ thousands) | ||||
| Reconciliation of net income (loss): | ||||
| Net Income (loss) | 183 | (182 | ) | |
| Adjustments: | ||||
| Depreciation of property and equipment | 12 | 9 | ||
| Amortization of other assets | 21 | 46 | ||
| Interest income | (20 | ) | (11 | ) |
| Non-cash stock-based compensation | 65 | 149 | ||
| Non-cash inventory write-offs | 34 | - | ||
| Adjusted EBITDA Income | 295 | 11 | ||
| (unaudited) | ||||
| Nine Months Ended September 30, | ||||
| Consolidated Results | 2024 | 2023 | ||
| (in $ thousands) | ||||
| Reconciliation of net loss: | ||||
| Net Income (loss) | (275 | ) | (921 | ) |
| Adjustments: | ||||
| Depreciation of property and equipment | 34 | 29 | ||
| Amortization of other assets | 68 | 134 | ||
| Interest expense | 1 | 1 | ||
| Interest income | (66 | ) | (36 | ) |
| Non-cash stock-based compensation | 91 | 662 | ||
| Non-cash inventory write-offs | 214 | 106 | ||
| Adjusted EBITDA Income (loss) | 67 | (25 | ) | |
Nephros believes that Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to Nephros’ financial condition and results of operations. Management does not consider Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recognized in Nephros’ financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management about which expenses and income are excluded or included in determining Adjusted EBITDA. To compensate for these limitations, management presents Adjusted EBITDA in connection with net income loss, the most directly comparable GAAP financial measure. Nephros urges investors to review the reconciliation of Adjusted EBITDA to net income loss and not to rely on any single financial measure to evaluate the business.
Conference Call Today at 4:30pm ET
Nephros will host a conference call today at 4:30pm ET, during which management will discuss Nephros’ financial results and provide a general business overview.
Participants may dial into the call as follows:
Domestic access: 1 (844) 808-7106
International access: 1 (412) 317-5285
Upon joining, please ask to be added into the Nephros conference call.
An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.
Alternatively, a replay of the call may be accessed until November 14, 2024 at 1 (877) 344-7529 or 1 (412) 317-0088 for international callers and entering replay access code: 5018166.
About Nephros
Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within medical and commercial markets, offering both proactive and emergency solutions for water management.
For more information about Nephros, please visit nephros.com.
Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’ expected future revenue, gross margins, cash flows and expectations on maintaining positive cash flow and profitability, and other future financial performance, the expected timing of the launch of new products and services, expected improvements in efficiency in the delivery of our products and services, and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including inflationary factors and general economic conditions, changes in business and competitive conditions, fluctuations in customer order volumes, unpredictability with respect to revenue derived from emergency response orders, the availability of capital when needed, dependence on third-party manufacturers and researchers, and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023, which it may update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has filed or will file hereafter. Nephros does not undertake any responsibility to update the forward-looking statements in this release.
Investor Relations Contacts:
Kirin Smith, President Robert Banks, CEO
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com
Robert Banks, CEO
Nephros, Inc.
(201)343-5202x121
robert.banks@nephros.com
| NEPHROS, INC. AND SUBSIDIARIES | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net revenue: | ||||||||||||||||
| Product revenues | $ | 3,472 | $ | 3,713 | $ | 10,186 | $ | 10,912 | ||||||||
| Royalty and other revenues | 46 | 29 | 106 | 72 | ||||||||||||
| Total net revenues | 3,518 | 3,742 | 10,292 | 10,984 | ||||||||||||
| Cost of goods sold | 1,369 | 1,548 | 4,044 | 4,600 | ||||||||||||
| Gross margin | 2,149 | 2,194 | 6,248 | 6,384 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 1,721 | 2,137 | 5,804 | 6,500 | ||||||||||||
| Research and development | 188 | 205 | 654 | 665 | ||||||||||||
| Depreciation and amortization | 34 | 55 | 101 | 163 | ||||||||||||
| Total operating expenses | 1,943 | 2,397 | 6,559 | 7,328 | ||||||||||||
| Operating income (loss) | 206 | (203 | ) | (311 | ) | (944 | ) | |||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense | - | - | (1 | ) | (1 | ) | ||||||||||
| Interest income | 20 | 11 | 66 | 36 | ||||||||||||
| Other income (expense), net | (43 | ) | 10 | (29 | ) | (12 | ) | |||||||||
| Total other expense: | (23 | ) | 21 | 36 | 23 | |||||||||||
| Net income (loss) | $ | 183 | $ | (182 | ) | $ | (275 | ) | $ | (921 | ) | |||||
| Net income (loss) per common share, basic | $ | 0.02 | $ | (0.02 | ) | $ | (0.03 | ) | $ | (0.09 | ) | |||||
| Net income (loss) per common share, diluted | $ | 0.02 | $ | (0.02 | ) | $ | (0.03 | ) | $ | (0.09 | ) | |||||
| Weighted average common shares outstanding, basic | 10,544,139 | 10,460,866 | 10,518,742 | 10,352,108 | ||||||||||||
| Weighted average common shares outstanding, diluted | 10,580,906 | 10,460,866 | 10,518,742 | 10,352,108 | ||||||||||||
| NEPHROS, INC. AND SUBSIDIARIES | ||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||
| (In thousands, except share and per share amounts) | ||||||||||
| (Unaudited) | ||||||||||
| ASSETS | September 30, 2024 | December 31, 2023 | ||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 2,457 | $ | 4,307 | ||||||
| Accounts receivable, net | 1,691 | 1,496 | ||||||||
| Inventory | 3,099 | 2,470 | ||||||||
| Prepaid expenses and other current assets | 109 | 132 | ||||||||
| Total current assets | 7,356 | 8,405 | ||||||||
| Property and equipment, net | 173 | 152 | ||||||||
| Lease right-use-of assets | 1,461 | 1,807 | ||||||||
| Intangible assets, net | 357 | 381 | ||||||||
| Goodwill | 759 | 759 | ||||||||
| License and supply agreement, net | 230 | 271 | ||||||||
| Other assets | 50 | 86 | ||||||||
| TOTAL ASSETS | $ | 10,386 | $ | 11,861 | ||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable | 398 | 873 | ||||||||
| Accrued expenses | 322 | 794 | ||||||||
| Current portion of lease liabilities | 338 | 446 | ||||||||
| Total current liabilities | 1,058 | 2,113 | ||||||||
| Lease liabilities, net of current portion | 1,154 | 1,390 | ||||||||
| TOTAL LIABILITIES | 2,212 | 3,503 | ||||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||||
| STOCKHOLDERS' EQUITY: | ||||||||||
| Preferred stock, $.001 par value; 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding September 30, 2024 and December 31, 2023. | - | - | ||||||||
| Common stock, $.001 par value; 40,000,000 shares authorized at September 30, 2024 and December 31, 2023; 10,544,139 and 10,543,675 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively. | 11 | 10 | ||||||||
| Additional paid-in capital | 152,844 | 152,754 | ||||||||
| Accumulated deficit | (144,681 | ) | (144,406 | ) | ||||||
| TOTAL STOCKHOLDERS' EQUITY | 8,174 | 8,358 | ||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 10,386 | $ | 11,861 | ||||||
FAQ
What was Nephros (NEPH) revenue in Q3 2024?
Did Nephros (NEPH) achieve profitability in Q3 2024?
What was Nephros (NEPH) gross margin in Q3 2024?
How much cash did Nephros (NEPH) have as of September 30, 2024?
